Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15536666 | 1.00 | TSHR (0.40) | TSHRKDM4ELMNAALDH1A1TP53 | |
| SCHEMBL15537049 | 0.89 | TSHR (0.43) | TSHRKDM4ELMNAALDH1A1TP53 | |
| SCHEMBL15537048 | 0.89 | TSHR (0.43) | TSHRKDM4ELMNAALDH1A1TP53 | |
| SCHEMBL15536633 | 0.86 | TSHR (0.40) | TSHRKDM4ELMNAALDH1A1TP53 | |
| SCHEMBL15536629 | 0.86 | TSHR (0.40) | TSHRKDM4ELMNAALDH1A1TP53 | |
| SCHEMBL15601984 | 0.83 | TSHR (0.40) | TSHRKDM4ELMNAALDH1A1TP53 | |
| SCHEMBL16713706 | 0.80 | BACE1 (0.44) | TSHRKDM4ELMNAALDH1A1TP53 | |
| SCHEMBL15602004 | 0.80 | BACE1 (0.44) | TSHRKDM4ELMNAALDH1A1TP53 | |
| SCHEMBL16713723 | 0.80 | TSHR (0.37) | TSHRKDM4ELMNAALDH1A1TP53 | |
| SCHEMBL15548089 | 0.80 | TSHR (0.37) | TSHRKDM4ELMNAALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2855469-B1 | 5-AMINO[1,4]THIAZINES AS BACE 1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2019-06-19 | — | — | EP | disclosed |
| EP-2855469-B1 | 5-AMINO[1,4]THIAZINES AS BACE 1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2019-06-19 | — | — | EP | disclosed |
| US-9273042-B2 | 5-amino[1,4]thiazines as BACE 1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273042-B2 | 5-amino[1,4]thiazines as BACE 1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273042-B2 | 5-amino[1,4]thiazines as BACE 1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150141413-A1 | 5-AMINO[1,4]THIAZINES AS BACE 1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-05-21 | — | — | US | disclosed |
| US-20150141413-A1 | 5-AMINO[1,4]THIAZINES AS BACE 1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-05-21 | — | — | US | disclosed |
| US-20150141413-A1 | 5-AMINO[1,4]THIAZINES AS BACE 1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-05-21 | — | — | US | disclosed |
| EP-2855469-A1 | 5-AMINO[1,4]THIAZINES AS BACE 1 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2015-04-08 | — | — | EP | disclosed |
| WO-2013174781-A1 | 5-AMINO[1,4]THIAZINES AS BACE 1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-11-28 | — | — | WO | disclosed |
| WO-2013174781-A1 | 5-AMINO[1,4]THIAZINES AS BACE 1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141413-A1 | 5-AMINO[1,4]THIAZINES AS BACE 1 INHIBITORS | BACE1, BACE2, PSEN1 | TSHR 4368/4885KDM4E 2171/4885LMNA 2749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.